Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma

Clinical Cancer Research

Volumn 16, Issue 16, 2010, Pages 4256-4267

  Smida, Jan ^a,b   Baumhoer, Daniel ^a,c   Rosemann, Michael ^a   Walch, Axel ^a   Bielack, Stefan ^d   Poremba, Christopher ^e,f   Remberger, Klaus ^g   Korsching, Eberhard ^h   Scheurlen, Wolfram ⁱ   Dierkes, Christian ^j   Burdach, Stefan ^b   Jundt, Gernot ^c   Atkinson, Michael J ^a   Nathrath, Michaela ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d OLGAHOSPITAL   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Research Park Trier   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ Nuremberg Hospital   (Germany)

^j JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ALLELIC IMBALANCE; ARTICLE; CANCER RELAPSE; CHILD; CHROMOSOME 10Q; CHROMOSOME 12Q; CHROMOSOME 6P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; ALLELIC IMBALANCE; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; YOUNG ADULT;

EID: 77955744323     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0284     Document Type: Article

References (46)

1. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90.
2. Al-Romaih K, Bayani J, Vorobyova J, et al. Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet 2003;144:91-9. (Pubitemid 36808954)
3. Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 2005;65:8142-50.
4. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003;38:215-25.
5. Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe 1983;4:135-41.
6. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol 1983;106 Suppl:21-4.
7. Bayani J, Zielenska M, Pandita A, et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003;36:7-16.
8. Boehm AK, Neff JR, Squire JA, Bayani J, Nelson M, Bridge JA. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Pediatr Pathol Mol Med 2000;19:359-76.
9. Bridge JA, Nelson M, McComb E, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997;95:74-87.
10. Zielenska M, Bayani J, Pandita A, et al. Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet 2001;130:14-21.
11. Man TK, Lu XY, Jaeweon K, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004;4:45.
12. Ozaki T, Schaefer KL, Wai D, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 2002;102:355-65.
13. Doak SH. Aneuploidy in upper gastro-intestinal tract cancers - a potential prognostic marker? Mutat Res 2008;651:93-104.
14. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-61.
15. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134:281-97.
16. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145:1-30.
17. Selvarajah S, Yoshimoto M, Ludkovski O, et al. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 2008;122:5-15.
18. Williams L, Somasekar A, Davies DJ, et al. Aneuploidy involving chromosome 1 may be an early predictive marker of intestinal type gastric cancer. Mutat Res 2009;669:104-11.
19. Heinsohn S, Evermann U, Zur Stadt U, Bielack S, Kabisch H. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 2007;30:1205-14.
20. Patino-Garcia A, Pineiro ES, Diez MZ, Iturriagagoitia LG, Klussmann FA, Ariznabarreta LS. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol 2003;25:362-7.
21. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 1996;14:467-72.
22. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466:2114-30.
23. Mohseny AB, Szuhai K, Romeo S, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009;219:294-305.
24. Ottaviano L, Schaefer KL, Gajewski M, et al. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010;49:40-51.
25. Freeman SS, Allen SW, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 2008;113:1453-61.
26. Pasic I, Shlien A, Durbin AD, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 2010;70:160-71.
27. Yen CC, Chen WM, Chen TH, et al. Identification of chromosomal aberrations associated with disease progression and a novel 3q13. 31 deletion involving LSAMP gene in osteosarcoma. Int J Oncol 2009;35:775-88.
28. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A 1998;95:13692-7.
29. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett 2005;230:6-19.
30. Shi Q, King RW. Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005;437:1038-42.
31. Chi YH, Jeang KT. Aneuploidy and cancer. J Cell Biochem 2007;102:531-8.
32. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
33. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol 2006;18:658-67.
34. Weaver BA, Cleveland DW. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res 2007;67:10103-5.
35. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A. Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas. Genes Chromosomes Cancer 1995;14:15-21.
36. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007;60:1-7.
37. Kasugai Y, Tagawa H, Kameoka Y, Morishima Y, Nakamura S, Seto M. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:8265-72.
38. Lu XY, Lu Y, Zhao YJ, et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-21 amplicon in osteosarcoma. Mol Cancer Res 2008;6:937-46.
39. Lau CC, Harris CP, Lu XY, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 2004;39:11-21.
40. Huang Y, Lin Z, Zhuang J, Chen Y, Lin J. Prognostic significance of α V integrin and VEGF in osteosarcoma after chemotherapy. Onkologie 2008;31:535-40.
41. Sulzbacher I, Birner P, Trieb K, Lang S, Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch 2002;441:345-9.
42. Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene 2008;27:2716-27.
43. Gamberi G, Benassi MS, Bohling T, et al. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 1998;55:556-63.
44. Benassi MS, Molendini L, Gamberi G, et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 1999;84:489-93.
45. Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer 1996;17:254-9.
46. Lopes MA, Nikitakis NG, Ord RA, Sauk J, Jr. Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws. Oral Oncol 2001;37:566-71.